Stockwinners Market Radar for August 04, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:29 EDT Hyundai to become investor in H2 Mobility - Hyundai (HYMLF) announced that it will become an investor in H2 Mobility, a company that sets up and coordinates the nationwide hydrogen infrastructure in Germany. The Hyundai Motor Company will be represented by Hyundai Motor Deutschland GmbH at the shareholders' meeting. The Cartel Office has already given the go-ahead for participation and the registration will be formally made shortly. Hyundai is the seventh shareholder alongside the founding members Total (TOT), Shell (RDS.A), OMV (OMVKY), Linde (LIN), Air Liquide (AIQUY) and Daimler (DDAIF).

18:07 EDT GeoPark doubles quarterly dividend to 4.1c per share from 2.1c - The dividend payable on August 31, 2021 to the shareholders of record at the close of business on August 17, 2021.

17:52 EDT Etsy drops 13% to $175.60 after Q2 results, Q3 guidance

17:41 EDT Clearwater Paper sees FY21 adjusted EBITDA impact of $25M-$27M - Sees raw material inflation impact of $60M to $70M in FY21, with pulp representing over half the total. Sees planned major maintenance outages $25M to $27M impact to adjusted EBITDA. Sees FY21 interest expense $36M-$38M. Sees FY21 capital expenditures $50M-$55M. Sees FY21 effective tax rate 26%-27%.

17:38 EDT Ethan Allen to change symbol - Ethan Allen announced that it will be changing its ticker symbol from (ETH) to (ETD). Effective on August 16, the company's common shares will trade on the New York Stock Exchange under the new symbol.

17:33 EDT Adaptive Biotechnologies appoints Nitin Sood as chief commercial officer - Adaptive Biotechnologies (ADPT) announced the appointment of Nitin Sood to the newly created position of chief commercial officer, effective immediately. Nitin brings more than 15 years of proven commercial experience at leading life sciences and diagnostics companies, most recently at Guardant Health (GH). In this new role, Nitin will oversee sales and marketing of immunoSEQ, clonoSEQ, and T-Detect, as well as commercial operations and market access. He will report directly to Chad Robins.

17:32 EDT Granite awarded $64M contract by Riverside County Transportation Department - Granite has been awarded a $64M contract for the Jurupa Road Grade Separation project by the Riverside County Transportation Department in Jurupa Valley, California. The contract award was included in Granite's second quarter committed and awarded projects. The scope of work includes separating Jurupa Road and the Union Pacific Railroad by constructing a grade separation and relocating existing rail spurs. As the daily vehicle traffic and train count continues to grow, the grade separation will improve community safety by mitigating traffic congestion, decreasing emergency vehicle response time, and reducing air pollution.

17:29 EDT Ryerson initiates cash dividend of 8c per share, authorizes share repurchase - Ryerson Holding has declared a quarterly cash dividend of 8c per share, or 32c on an annualized basis, on the company's shares of common stock. Ryerson's first dividend payment will be made on September 16 to stockholders of record as of the close of business on August 16. The Board also approved a share repurchase program authorizing the company to purchase up to an aggregate of $50M of the company's common stock over the next two-year period.

17:24 EDT EA says it will continue to invest in 'Star Wars Jedi: Fallen Order' series

17:16 EDT EA says 'Mass Effect: Legendary Edition' performed above expectations - Says delivered "very strong" results. Sees pandemic-related growth continuing well into the future. Says "Mass Effect: Legendary Edition" performed well above company expectations. Says main growth driver is live services. Says "It Takes Two" showed continued strength in Q1. Says Q1 outperformance partially driven by "It Takes Two." Comments taken from Q1 earnings conference call.

17:07 EDT Regeneron: NEJM publishes 'positive' Phase 3 trial results for REGEN-COV - Regeneron Pharmaceuticals announced that the New England Journal of Medicine published positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV to prevent COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial met its primary endpoint, reducing the risk of symptomatic infections by 81%, with a 93% reduction of symptomatic infections after the first week, and no dose-limiting toxicities observed. "This peer-reviewed NEJM publication demonstrates that REGEN-COV provides rapid and robust protection to prevent SARS-CoV-2 infection, and follows data showing that REGEN-COV maintains effectiveness against all variants of concern," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer at Regeneron. "Despite the increased uptake of vaccines, SARS-CoV-2 has not been eradicated. In addition, growing evidence suggests that a substantial number of individuals, such as the immunocompromised, will not respond satisfactorily to vaccines. Thus, we believe there is a significant need for complementary medicines such as REGEN-COV to help prevent the spread of SARS-CoV-2 infection, particularly in these immunocompromised patients."

17:04 EDT Datadog launches Datadog Cloud Security Platform - Datadog launched the Datadog Cloud Security Platform. This new offering enables organizations to use a single platform to correlate security insights with monitoring data across infrastructure, network and application tiers, providing Security teams with the visibility they need to understand and respond to potential threats faster. Datadog's Cloud Security Platform enables DevOps and Security teams to access a shared source of truth supported by a common data model.

16:58 EDT NexTier Oilfield to acquire Alamo Pressure Pumping for $268M - NexTier Oilfield Solutions announced that it has reached an agreement to acquire 100% of the ownership interests of Alamo Pressure Pumping for a transaction valuation of approximately $268M, as further described below. The transaction is expected to be completed by August 31, subject to customary closing conditions and approvals. Alamo, founded in 2017 and headquartered in Midland, Texas, is a leading Permian pressure pumper based on next generation horsepower and active fleets. Acquired assets include 9 hydraulic fracturing fleets comprised of 460,000 horsepower, approximately 92% of which is Tier IV DGB capable. Alamo operates exclusively in the Permian Basin and primarily out of Midland. Alamo achieved $68M of EBITDA in 2020.

16:54 EDT Evolent Health to acquire Vital Decisions for $85M - Evolent Health and WindRose Health Investors announced that they have entered into a definitive agreement for Evolent to acquire WindRose's portfolio company Vital Decisions for $85M, with an additional earn out of up to $45M. Vital Decisions will report into Evolent's specialty management offering, New Century Health, and will be consolidated into Evolent's Clinical Solutions segment. Founded in 2006, and headquartered in New Jersey, Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout every step of their health journey and, in particular, as they approach the end of life.

16:53 EDT Warrior Met Coal not providing FY21 guidance - The company states: "Due to ongoing uncertainty related to negotiations with the UMWA, the Chinese ban on Australian coal and other potentially disruptive factors, Warrior will not be providing full year 2021 guidance at this time. The Company expects to return to providing guidance once there is further clarity on these issues. Warrior continues to appropriately adjust its operational needs, including managing expenses, capital expenditures, working capital, liquidity and cash flows. The Company has delayed the development of the Blue Creek project and its Stock Repurchase Program also remains temporarily suspended, while it focuses on preserving cash and liquidity."

16:51 EDT Uber: New driver sign ups increased 30% in July m/m

16:48 EDT Acadia Pharmaceuticals cuts FY21 NUPLAZID net sales guidance to $480M-$515M - The company states: "NUPLAZID net sales guidance is decreased to $480 to $515 million from the previous range of $510 to $550 million as a result of the continued impact of the pandemic with fewer Parkinson's disease patient office visits and lower occupancy rates at long-term care facilities, as well as a revised gross-to-net expectation of approximately 20% compared to prior expectation of high teens."

16:48 EDT Terreno Realty raises quarterly dividend 17.2% to 34c per share - Terreno Realty declared a regular cash dividend for the quarter ending September 30, 2021 of $0.34 per common share; an increase of 17.2% over the prior dividend level. The dividend will be payable on October 15, 2021 to common stockholders of record at the close of business on October 1, 2021.

16:47 EDT Uber expects to start delivering on Postmates syngery targets in Q3

16:45 EDT Uber: Drivers increased 75% during Q2, CEO says

16:44 EDT Uber: 90% of idle drivers expected back next month - Comments taken from Q2 earnings conference call.

16:43 EDT Ezcorp CEO sees continuing trend of improving financial performance - CEO Jason Kulas stated, "Looking ahead, we remain well positioned to continue our trend of improving financial performance, and are excited about the increasing earnings power of the platform. Pawn transaction activity continues to rebuild, driving PLO balances closer to pre-pandemic levels, which will drive accelerating pawn service charge revenue in the coming quarters given the natural lag between pawn originations and related fees. In addition, we remain on track to realize meaningful cost savings this year and beyond, even assuming store-level expenses trend higher to meet accelerating transaction volumes. And, we maintain a strong and liquid balance sheet to fund accelerating pawn demand and capitalize on acquisition opportunities that further enhance our scale-enabled and geographically diverse footprint and generate strong returns on investment."

16:39 EDT Sabra Health Care CFO Harold Andres to retire - Sabra Health Care "announced that Harold Andrews, CFO and Secretary, has decided to retire effective December 31, 2021 and Michael Costa, Sabra's Executive Vice President - Finance and Chief Accounting Officer, is expected to be elevated to the role of Sabra's Chief Financial Officer effective January 1, 2022. Mr. Andrews is expected to remain in a consulting role with Sabra pursuant to a two-year consulting arrangement that Sabra expects to enter into with Mr. Andrews at the time of his retirement. Sabra will also begin searching for a replacement for Mr. Costa's current position with the goal of filling that role by year end."

16:38 EDT Laredo Petroleum sees Q3 total production 74.5-77.5 MBOE per day - Sees Q4 total production 77.5-80.5 MBOE per day.

16:37 EDT Barrett Business sees FY21 gross billings up 6%-8% - Sees FY21 effective tax rate 22%-24%.

16:30 EDT PDC Energy announces long-term environmental performance goals - By 2025, the Company is committed to further reducing its GHG and methane intensities by 60 percent and 50 percent, respectively. Further, the Company has significantly accelerated its commitment in aligning with the World Bank in achieving zero routine flaring by 2025 as opposed to its prior commitment of 2030. Additionally, the Company plans to invest nearly $75 million through its asset retirement obligations to plug and reclaim more than 1,000 high emission intensity legacy vertical wells by 2025. The Company's reclamation efforts are aimed at nearly all of its vertical wells and are expected to meaningfully reduce its emission intensity and operating footprint.

16:29 EDT PDC Energy sees more than $800M of free cash flow for FY21 - Anticipate more than $800 million of FCF assuming $65 per Bbl WTI, $3.50 per Mcf NYMEX natural gas and NGL realizations of approximately $20 per Bbl for the remainder of the year.Expected oil and gas capital investments between $550 to $600 million, which incorporates anticipated cost inflation of approximately ten percent per well in the Wattenberg for the remainder of the year. Anticipated oil production of 64,000 to 66,000 Bbls per day and expected total production of 190,000 to 195,000 Boe per day.

16:22 EDT Maxar Technologies awarded contract to build new satellite for SiriusXM - Maxar Technologies "announced the company will manufacture a new geostationary communications satellite for longtime customer SiriusXM. The SXM-9 satellite will be based on Maxar's proven 1300-class platform and built at the company's manufacturing facility in Palo Alto, California. It is expected that SXM-9 will launch in 2024."

16:21 EDT Frontier Group sees Q3 capacity 2%-4% Vs Q319 - Sees

16:18 EDT Marathon Oil backs FY21 CapEx view of $1B - The company is raising the midpoint of its 2021 full year U.S. oil-equivalent production guidance by 5,000 net boed. All other full year 2021 production guidance remains unchanged. Due primarily to continued commodity price strength, the company is raising its 2021 E.G. equity method income guidance to $180M-$200M, an increase of over 70% at the midpoint.

16:16 EDT PetIQ announces departure of CFO John Newland, search for successor - PetIQ announced that after more than seven years with the company, John Newland will retire from his role as CFO, effective March 31, 2022, following its reporting of FY21 results. The company has initiated a search to identify a new CFO.

16:10 EDT Inogen expects net losses in both Q3 and Q4, net loss for FY21

16:10 EDT TechTarget acquires Xtelligent Healthcare Media, no terms - TechTarget announced the acquisition of Xtelligent Healthcare Media LLC, a leading online marketing services, media and data company that focuses on the intersection of healthcare and technology. It operates a portfolio of ten websites with independent editorial coverage and vendor content assets related to areas such as telehealth, healthcare analytics, revenue cycle management, healthcare IT security and infrastructure, and other areas of healthcare purchase decisions. "We are very excited to join TechTarget and extend our combined audiences and offerings into new markets," said Sean Brooks, Co-Founder and CEO, Xtelligent Media. "TechTarget's experience and success with first party data, combined with their deep understanding of the B2B Media & Data space, will help us continue to grow and offer customers new opportunities to reach and engage highly targeted healthcare technology decision-makers."

16:07 EDT Uber reports Q2 adjusted EBITDA of ($509M), up $328M y/y

16:03 EDT Booking CEO encouraged by 'another quarter of meaningful sequential improvement' - "We are encouraged by another quarter of meaningful sequential improvement in booking trends with second quarter room nights increasing 59% versus the first quarter of 2021, primarily driven by stronger results in Europe and in the U.S. We remain focused on strengthening our core accommodation business and driving benefits to our travelers and our accommodation supply partners alike. In addition, we continue to execute against our strategic priorities, including our Connected Trip vision, which we believe will further enhance our core accommodation business," said Glenn Fogel, CEO of Booking Holdings.

15:32 EDT Teck Resources says oxygen plant at Trail Operations has been shut down - Teck Resources announced that smoke from wildfires in southwestern British Columbia has affected operations at its Trail Operations metallurgical facility. Specifically, the oxygen plant at Trail has been shut down due to poor ambient air quality, and the usual mitigation measures have not been adequate to deal with conditions. Zinc refining operations are running at approximately 70% of normal rates. Lead refining continues to operate normally; however, the lead smelting operations have been temporarily idled. Resumption of full production will depend on improvements in air quality. Regional air quality conditions are being actively monitored and Trail Operations has response plans in place to protect employee safety.

14:02 EDT Gentex approves additional share repurchase authorization of 25M shares - Gentex announced that its board of directors recently declared a quarterly cash dividend of 12c per share that will be payable on October 21 to shareholders of record of the common stock at the close of business on October 8. Additionally, Gentex's board of directors approved an additional share repurchase authorization of 25M shares. "Despite the issues created by the pandemic over the last 18 months, we have been focused on creating and implementing the financial discipline that was needed to support profitability, cash generation and new product development. Our capital allocation strategy is designed to supplement our company's growth with consistent and appropriate utilization of the company's cash flow. This strategy prioritizes reinvestment into the company by funding capital expenditures and provides the ability to acquire new and exciting technologies that fit well with our technology portfolio. Beyond that, our strategy focuses on M&A, a consistent dividend and a very meaningful repurchase philosophy," said Gentex President and CEO Steve Downing.

13:31 EDT NVR authorizes repurchase of $500M in common stock - NVR, Inc. announced that its board of directors has authorized the repurchase of $500M of its outstanding common stock. The purchases will occur from time to time in the open market and/or in privately negotiated transactions as market conditions permit. The company indicated that the authorization is a continuation of the stock repurchase program that began in 1994 and "is consistent with NVR's strategy of maximizing shareholder value." NVR added: "Consistent with prior authorizations, this new authorization prohibits the company from purchasing shares from the company's officers, directors, Profit Sharing/401(k) Plan Trust or Employee Stock Ownership Plan Trust."

12:59 EDT Sorrento says salicyn-30 results in rodent model of SARS-CoV-2 'promising' - Sorrento Therapeutics, in collaboration with The Scripps Research Institute of La Jolla, announced that the American Chemical Society has published the article "Salicylanilides Reduce SARS-CoV-2 Replication and Suppress Induction of Inflammatory Cytokines in a Rodent Model," which describes a salicylanilide library screened in a SARS-CoV-2 cell activity assay. "Based on this screening effort, the most efficacious derivative, Salicyn-30, was further evaluated in a prophylactic mouse model of SARS-CoV-2 infection. This analysis demonstrated that Salicyn-30 can potentially reduce viral loads, modulate key cytokines, and mitigate severe weight loss involved in COVID-19 infections. Moreover, based on their mechanism of action, Salicyn-30 and other lead compounds may be equally effective against recent emerging SARS-CoV-2 variants. The combination of anti-SARS-CoV-2 activity, cytokine inhibitory activity, variant indifference and a previously established favorable pharmacokinetic profile for the lead Salicyn-30 renders salicylanilides in general, and Salicyn-30 in particular, as promising therapeutics for COVID-19," the company stated.

12:46 EDT Rolls-Royce confirms exclusive talks with consortium regarding ITP Aero sale - Rolls-Royce, in a statement issued to the London Stock Exchange, notes recent speculation in the media about a possible sale of ITP Aero. "Rolls-Royce confirms it has decided to enter into exclusive discussions with a consortium led by Bain Capital on a potential sale of the business. There can be no certainty that an agreement will be reached. Rolls-Royce will make a further statement as appropriate," the company said.

12:35 EDT Occidental Petroleum sees Q3 oil & gas production 1,130-1,160 MBoed - Sees Q3 OxyChem pre-tax income roughly $390M. Guidance taken from Q2 earnings call presentation slides.

12:05 EDT AbbVie: JAMA data shows Rinvoq 'superior' vs. Dupixent in AD study - AbbVie announced that JAMA Dermatology has published 24-week results from the Phase 3b Heads Up study evaluating the efficacy and safety of RINVOQ versus DUPIXENT - both as monotherapy treatments - in adults with moderate to severe atopic dermatitis who were candidates for systemic therapy. The publication expands upon previously announced topline results and showed upadacitinib achieved superiority compared to dupilumab for the primary endpoint, the proportion of patients with at least a 75 percent improvement in the Eczema Severity Index at week 16.1 Of those treated with upadacitinib, 71 percent achieved EASI 75 at week 16 compared to 61 percent of those treated with dupilumab.1 Additionally, upadacitinib demonstrated statistically significant greater efficacy across all ranked secondary endpoints compared to dupilumab through week 16, including early reduction in itch and rates of skin clearance improvement. "In this study, upadacitinib 30 mg demonstrated a more rapid onset of action compared to dupilumab, with patients experiencing a reduction in itch at one week and skin clearance improvements at two weeks. In addition, more upadacitinib-treated patients achieved high levels of skin clearance, such as EASI 90 and 100, by 16 weeks of treatment," said Andrew Blauvelt, MD, MBA, lead investigator for the Heads Up study and president of Oregon Medical Research Center in Portland, Oregon. "The results from this important comparative study will help inform how physicians work with their patients to set treatment goals for atopic dermatitis." Results for select ranked secondary endpoints include: After one week of treatment, the upadacitinib 30 mg treatment group had a 31 percent reduction in itch. After two weeks of treatment, 44 percent receiving upadacitinib achieved EASI 75 versus 18 percent receiving dupilumab. At 16 weeks, 28 percent of people treated with upadacitinib achieved clear skin and 61 percent achieved almost clear skin, compared to 8 percent and 39 percent, respectively, of those treated with dupilumab.

12:01 EDT W&T Offshore falls -19.6% - W&T Offshore is down -19.6%, or -80c to $3.25.

12:00 EDT Inspire Medical rises 13.0% - Inspire Medical is up 13.0%, or $24.26 to $211.26.

12:00 EDT Coursera rises 15.3% - Coursera is up 15.3%, or $5.47 to $41.15.

11:16 EDT New York Community Bancorp, Flagstar receive shareholder approval for merger - New York Community Bancorp (NYCB) and Flagstar Bancorp (FBC) announced that, at their respective special meetings of shareholders, they each received the necessary shareholder approval for the consummation of their planned merger. The transaction is expected to close during the fourth quarter, subject to the satisfaction of certain closing conditions and the receipt of all necessary regulatory approvals. Upon closing, the combined company will have $85B in total assets, operate nearly 400 traditional branches in nine states, and 86 retail lending offices across a 28-state footprint. It will have its headquarters on Long Island, N.Y. with regional headquarters in Troy, Michigan, including Flagstar's mortgage business. The transaction creates an organization with significant scale in several lines of business, accelerates our transition towards building a dynamic commercial bank, drives strong financial results and enhances capital generation.

11:06 EDT BOK Financial appoints Stacy Kymes as president, CEO - BOK Financial Corporation has named Stacy Kymes president and CEO effective April 1, 2022, upon the retirement of Steven Bradshaw. Kymes has also been appointed to the company's board of directors effective August 3. Kymes, who has been with the company for 25 years, has served in various roles with the company, including chief auditor, director of mergers and acquisitions, and chief credit officer. In his current role as COO, he leads BOKF's revenue-generating business lines including Specialized Banking, Regional and Commercial Banking, Consumer Banking, and Wealth Management.

10:56 EDT General Motors: 2H production depends on chip supply

10:35 EDT Dr. Reddy's to sell U.S., Canada rights for Elyxyb to BioDelivery Sciences - Dr. Reddy's Laboratories (RDY) announced that it has entered into a definitive asset purchase agreement, pursuant to which Dr. Reddy's will sell its U.S. and Canada territory rights for Elyxyb 25 mg/mL to BioDelivery Sciences International (BDSI). Under the terms of agreement, Dr.Reddy's will receive $6M upfront upon closing followed by $9M one year from closing. Further, Dr. Reddy's is eligible to receive event based, sales based milestones and quarterly earn-out payments. Elyxyb, previously known as DFN-15, is indicated for the acute treatment of migraine with or without aura in adults. The closing of the transaction is subject to satisfactory completion of customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

10:29 EDT FinCanna Capital signs strategic agreement with Sense Distribution - FinCanna Capital is pleased to announce that its portfolio company, QVI Inc., doing business as "The Galley", has signed a strategic agreement with Sense Distribution which will significantly expand The Galley's retail distribution network across California and provide additional distribution revenues for QVI Founded in 2019, Sense Distribution is a privately-owned cannabis distributor headquartered in Santa Rosa CA. Currently servicing 90 dispensaries throughout the state, Sense offers full distribution services to a unique lineup of brands as well as its own line of commercial cannabis infused ingredients for edible creation.

10:20 EDT Wrap Technologies announces follow-on international order for BolaWrap - Wrap Technologies announced a follow-on international order for 1,500 BolaWrap products and accessories. The order is the single largest received by the company to date, the company said in a statement. "This customer had ordered demonstration BolaWrap devices previously and is now expanding the use of our technology as their Ministry looks to prevent escalation of force," said Tom Smith, CEO and President of WRAP. "We initially utilized Zoom to virtually demonstrate BolaWrap and its benefits with our distributor to the end-user. This order illustrates how law enforcement agencies around the world are still able to understand the value of our technology despite presenting virtually with our distributors during the global pandemic. We will continue driving our international sales moving forward with the support of our local distributors." WRAP received the order for its BolaWrap in the second quarter of 2021, which was partially shipped in that period. The Company expects to fulfill the remainder during the second half of this year.

10:16 EDT General Motors sees 2H commodity expense to be $1.5B-$2B higher than 1H

10:16 EDT Horizon Therapeutics jumps on earnings beat, stronger guidance - Shares of Horizon Therapeutics (HZNP) are on the rise on Wednesday after the company reported better-than-expected quarterly results and increased its full year revenue guidance. RESULTS: Horizon Therapeutics reported second quarter earnings per share of $1.62, which was better than the expected 88c. This compares to earnings of 40c per share a year ago. The company also reported revenue of $832.5M for the quarter, with consensus at $685.03M. This compares to year-ago revenues of $462.8M. Additionally, Horizon increased its full year 2021 net sales guidance to $3.025B-$3.125B, and its full year 2021 adjusted EBITDA guidance to $1.26B-$1.30B. PRICE ACTION: In Wednesday morning trading, shares of Horizon Therapeutics have gained almost 10% to $109.65.

10:12 EDT Fisker, Bridgestone partner on Fisker Ocean electric vehicle - Fisker (FSR) and Bridgestone (BRDCY) are announcing a new partnership. Fisker has selected Bridgestone as the exclusive tire partner for the much-anticipated Fisker Ocean all-electric SUV. The Fisker Ocean will make its global debut at the upcoming 2021 Los Angeles Auto Show, with production starting on November 17, 2022. The Fisker Ocean features extensive use of recycled materials, including a fully vegan interior, and will come with an optional photovoltaic solar roof. The Fisker Ocean will sit on custom-developed Bridgestone Potenza Sport tires for vehicles sold in Europe and select models sold in North America. The bespoke Potenza Sport tires deliver an optimal driving experience focused on ride comfort and handling stability, and are engineered for low rolling resistance, which conserves the Fisker Ocean's battery energy by ensuring that less power is required to move the vehicle's tires.

10:09 EDT Malaysia Airlines partners with GE Digital to modernize fuel analytics platform - Malaysia Airlines and GE Digital are pleased to announce a collaboration to transform and modernize the airline's fuel efficiency program by adopting GE Digital's Fuel Insight and FlightPulse aviation software as part of the airline's on-going initiative to meet its sustainability goals. Malaysia Airlines has implemented various initiatives including efficiency measures, investments in sustainability solutions, and waste reduction across its operations to address sustainability goals. The fuel efficiency program has been running for more than a decade, contributing to a 15% fuel burn improvement recorded over the past eight years. Data analytics has been a cornerstone of the program with various improvements made in systems infrastructure and capabilities. As a part of this focus, the airline embraces technologies by GE Digital to facilitate efficient and digitally-connected operations.

10:07 EDT GM Bolt recall doesn't impact new Bolt EV, EUV, Ultium cells, CEO says

10:05 EDT North Island Credit Union moves investment program to AFIG - Ameriprise Financial announced that North Island Credit Union, a division of California Credit Union, has moved its investment program to the Ameriprise Financial Institutions Group. Serving more than 165,000 members with 25 branches, the credit union selected the Ameriprise Financial platform to enhance and expand its investment solutions offering for its members. With 11 financial advisors across Southern California, the investment program currently manages $750 million in brokerage assets. To reflect its newly expanded services, the credit union has rebranded its investment group to North Island Credit Union Wealth Management, a financial advisory practice of Ameriprise Financial Services, LLC.

10:03 EDT Enzyvant announces publication of results from trials of RVT-802 - Results from clinical trials of Enzyvant's investigational RVT-802. engineered human thymus tissue implanted in 105 pediatric patients, were published today in The Journal of Allergy and Clinical Immunology. Pediatric congenital athymia is ultra-rare with an estimated incidence in the U.S. of ~17 to 24 live births each year. Children who have this condition are born without a thymus, which leads to profound immunodeficiency, life-threatening immune dysregulation, and high susceptibility to potentially fatal infections. With only supportive care, children with congenital athymia typically die by age two or three. There are currently no FDA-approved treatments for congenital athymia. Engineered human thymus tissue has been studied by researchers across 10 clinical studies at a single center for more than 25 years. RVT-802 clinical trials at Duke University Medical Center have been supported with funding from Enzyvant. Ten prospective single-arm, open-label studies with patient enrollment from 1993 to 2020 form the basis of the investigational RVT-802 data set. One hundred and five patients were surgically implanted with RVT-802 under one of 10 Institutional Review Board-approved protocols. Ninety-five patients were included in the Efficacy Analysis Set and 105 patients were included in the Safety Analysis Set. Patients were tested in clinical trials after implantation with RVT-802 to detect naive T cells using flow cytometry at three, six, and 12 months. Survival rates were analyzed with the longest follow-up period of 25.5 years. In the EAS, Kaplan-Meier estimated survival rates were 77% at one year and 76% at two years. For patients who were alive at one year post implantation, the Kaplan-Meier estimated long-term survival rate was 93% at a median follow-up time of 10.9 years. Patients in the clinical trials started out with very few naive T cells but those who survived to one year after implantation developed mature and naive T-cell levels sufficient to fight infection and support survival. To explore the number of infections over time following treatment with investigational RVT-802, the number of infections were analyzed for the first six months post implantation and compared to the number of infections in the second six months after implantation. There was a significant decrease in the number of infections in the second six months. The number of infections were also compared between the first and second year after implantation with similar results. There was a significant decrease in the number of infections in year two after implantation. The most common adverse reactions reported following implantation with investigational RVT-802 were thrombocytopenia, neutropenia, pyrexia, proteinuria, alopecia, wound dehiscence, Coombs-positive hemolytic anemia, autoimmune hemolytic anemia, hemolysis, rash, blood bicarbonate decrease, diarrhea, and autoimmune hepatitis. Of the 105 patients, 28 patients died after receiving RVT-802, including 22 deaths in the first year after implantation. Causes of death in the first year included 13 deaths due to infection or complications due to infection, five deaths due to respiratory failure/hypoxia, three deaths due to hemorrhage-related events, and one death due to cardiorespiratory arrest. Of the six patients who died more than one year post implantation, two died due to respiratory failure and one died due to each of the following: cardiopulmonary arrest, intracranial hemorrhage, infection, and unknown cause.

10:00 EDT Team falls -14.8% - Team is down -14.8%, or -97c to $5.60.

10:00 EDT W&T Offshore falls -17.5% - W&T Offshore is down -17.5%, or -71c to $3.34.

10:00 EDT Inspire Medical rises 13.6% - Inspire Medical is up 13.6%, or $25.40 to $212.40.

09:59 EDT CordovaCann completes sale-leaseback, finances Oregon expansion - CordovaCann provides an update on its Cannabilt Farms licensed cannabis cultivation operation in Clackamas, Oregon. Cordova OR Operations, LLC, a wholly-owned subsidiary of the Company, has sold all of its land, building and equipment for $2.2M and entered into an agreement to lease the Property from the buyer. The Lease will allow Cannabilt to operate on the Property for ten years, and provides options for two subsequent ten year renewal periods. Proceeds from the sale will be used to retire debts related to the Property and to finance the planned expansion at Cannabilt. A total of $600,000 of the purchase price has been placed in escrow by the buyer to allow Cannabilt to complete its buildout of the facility. The Lease was signed on July 20, 2021 and commenced on August 1, 2021. Cannabilt will pay no rent during the first three months of the lease and will pay $22,000 per month for the reminder of the first year, with annual payment escalators thereafter. The facility buildout includes expanding the cultivation facility to the maximum 10,000 square feet of indoor cultivation canopy that is permitted under the Tier II Marijuana Production License granted by the Oregon Liquor Control Commission. The Company expects to be cultivating under the entire canopy by the end of 2021. Cannabilt will leverage the distribution channel already established and will continue to expand the wholesale and retail relationships for the increase in output. The buildout also includes the completion of a 14,000 sq. ft. extraction and manufacturing facility on the premises that is in the licensing process with the OLCC. Once completed and licensed, this facility will allow the Company to produce a wide variety of cannabis derived products for consumption across Oregon. Having both cultivation and manufacturing facilities will optimize the operation and drive incremental revenue and cash flow for Cordova, while allowing the Company to build brand recognition in the state.

09:47 EDT OneConnect falls -16.2% - OneConnect is down -16.2%, or -$1.21 to $6.25.

09:47 EDT Genesis Energy falls -18.0% - Genesis Energy is down -18.0%, or -$1.82 to $8.28.

09:47 EDT Inspire Medical rises 11.7% - Inspire Medical is up 11.7%, or $21.87 to $208.87.

09:42 EDT Robinhood halts again for volatility with shares up 65% to $77.03

09:40 EDT Robinhood trading resumes, shares up 44% to $67.18

09:38 EDT Moxian Inc trading resumes

09:35 EDT Robinhood Markets Inc (Class A Stock) trading halted, volatility trading pause

09:28 EDT Ford reports July U.S. sales down 31.8% to 120,053 vehicles - "In addition to the sales we delivered in July, our retail order bank increased over 70,000 units, excluding our Bronco and Maverick retail orders, which is 10 times higher than we were a year ago. Our newest products, including F-150 PowerBoost, Mustang Mach-E, Bronco and Bronco Sport, are conquesting at a rate that is almost 14 points higher than Ford overall. With our strong portfolio of new products, robust transaction pricing and a big order bank, we are perfectly positioned for significant growth as the semiconductor chip situation improves," said Andrew Frick, vice president, Ford Sales U.S. and Canada. Mustang Mach-E July sales grew 15.8% in July compared to June and F-150 Lightning reservations exceeded 120,000, Ford noted.

09:16 EDT BorgWarner closes contracts to supply dual inverters to two Chinese OEMs - BorgWarner closed contracts to supply dual inverters for two premier Chinese original equipment manufacturers, or OEMs. The dual inverters will be featured on both hybrid electric vehicles and plug-in hybrid electric vehicle versions of the GWM LEMON platform, and the other major Chinese OEM will utilize the technology on its own HEV and PHEV passenger car models. Production for the GWM dual inverter is currently underway, with and without a DC/DC converter option, which was launched on several 2021 GWM models. The project with the other major Chinese OEM is planned for 2023 models.

09:12 EDT Einhorn: Atlas Air benefiting from structural shortage of air cargo capacity

09:11 EDT Apollo Global to acquire majority stake in AS Graanul Invest - Apollo Global Management announced that funds managed by its affiliates have agreed to acquire a majority stake in AS Graanul Invest, the largest producer of sustainable wood pellets in Europe - and one of the largest producers globally. "With the accelerating Energy Transition in Europe and globally, baseload renewable energy sources such as biomass are a critical and enabling piece of the puzzle, by providing dispatchable electricity and heat to must-run facilities," said Apollo's Brad Fierstein. "Raul and the Graanul team are best-in-class in this industry and have done an excellent job scaling and positioning the business to play a critical role supporting this energy transition, as a reliable supplier to its customers, with proven sustainability." The transaction, which is expected to close later in 2021, is subject to antitrust and regulatory approvals and other customary closing conditions.

09:10 EDT Greenlight's David Einhorn sees 'structural change' in inflation - Greenlight's David Einhorn says that while some inflation will prove short-lived, he thinks we have reached a structural change in inflation.

09:09 EDT IntelGenx appoints Srinivas Rao, Frank Stegert to board of directors - IntelGenx Technologies Corp. (IGXT) announced the appointments of Srinivas Rao, M.D., Ph.D. and Frank Stegert to its Board of Directors. The appointments of the two new directors were made pursuant to the previously disclosed purchaser rights agreement by and between the Company and ATAI Life Sciences AG (ATAI). With the appointments, the size of the Company's Board of Directors increased from six to eight. Srinivas Rao has served as atai's Chief Scientific Officer since April 2019 and Frank Stegert has served as atai's Vice President, Investment Management and Operations since January 2021, having also served as a part-time consultant for atai prior to joining full-time. Dr. Rao has been assigned to the Compensation Committee of the Board and Mr. Stegert has been assigned to the Corporate Governance and Nominations Committee of the Board. Each new director will serve until the 2022 annual meeting of the Corporation's stockholders and until his successor is duly elected and qualified.

09:09 EDT Chatham Lodging acquires extended-stay hotels in Austin, Texas - Chatham Lodging Trust a hotel real estate investment trust "focused on investing in upscale, extended-stay hotels and premium-branded, select-service hotels, today announced that the company has acquired in an off-market transaction two, high-quality, premium-branded hotels comprising 269 rooms at the Domain in Austin, Texas, for $71.2M or approximately $265,000 per room . The acquired hotels include the 132-room Residence Inn Austin Domain, which opened in July 2016, and the 137-room TownePlace Suites Austin Domain, which opened in June 2021. Upon stabilization, the Austin Acquisitions are expected to generate an estimated NOI yield of 8.0% to 8.5%.," said the company

09:07 EDT Verizon, Parrot, Skyward bring 4G LTE connected drone to US market - Verizon, Parrot, and Skyward announced an exclusive partnership to bring the first out-of-the-box 4G LTE connected drone solution to the United States. Parrot ANAFI Ai is the first and only off-the-shelf drone to connect to Verizon's 4G LTE network. Verizon 4G LTE connectivity is provided exclusively to Skyward subscribers at no additional cost. Parrot ANAFI Ai is a compact professional drone, built for work, setting a new communications standard, open to developers, with a full open source app, autonomous 1 click photogrammetry and new levels of cybersecurity. The Skyward Connected Drone Solution with Parrot's ANAFI Ai is making complex missions for photogrammetry, mapping, modeling in construction, infrastructure, inspection & surveying, public safety and enterprise use quicker. "Enterprise drone programs are pushing the limits of technology available today and advanced operators are ready for a connected, trusted, and capable drone to take their drone programs to the next level," said Mariah Scott, Head of Verizon Robotics Business Technology. "Parrot ANAFI Ai connected to Verizon 4G LTE marks an industry milestone toward distributed, remote, persistent operations that lets users fly to anywhere from anywhere with near real time data transfer." The Skyward Connected Drone Solution with Parrot ANAFI Ai on Verizon 4G LTE will be available in the second half of 2021 through Skyward.

09:06 EDT Amazon says adding six new cities for 'faster same-day delivery' - In a post to the corporate blog, Amazon Staff wrote: "Since launching Same-Day Delivery, we've continued to bring customers new levels of convenience and more delivery options to choose from. Our move to make Same-Day Delivery even faster is just one example of a delivery innovation that gives customers more choice, speed, and convenience when receiving their packages. Last year, we announced that Amazon Prime members in Philadelphia, Phoenix, Orlando, and Dallas became eligible for even faster Same-Day Delivery with the ability to order from up to 3 million items across a dozen categories, including Baby, Beauty & Health, Kitchen & Dining, Electronics, Pet Supplies, and more. In November, we expanded the service to two more cities by adding Nashville and Washington, D.C. Today, to celebrate the one-year anniversary of launching faster Same-Day Delivery, we're announcing availability in six more cities. Prime members in Baltimore, Chicago, Detroit, Tampa, Charlotte, and Houston can now enjoy fast delivery-from click to doorstep in as fast as five hours. With faster Same-Day Delivery, customers can order items for delivery throughout the day. They can even place an order by midnight for overnight delivery. Customers simply select 'Overnight by 8 a.m.' to have their orders on their doorstep the next morning before heading out for the day. The service is free to Prime members on qualifying orders over $35."

09:06 EDT U.S. Navy awards L3Harris $393M undersea training range contract - The U.S. Navy has awarded L3Harris Technologies a $393M contract to install increments II and III of the Undersea Warfare Training Range, USWTR. The award follows nearly 10 years of execution by L3Harris on Increment I and will replace and upgrade the remaining underwater training range sites. USWTR Increment I included installing the ocean sensor and shore electronics subsystems instrumenting the approximately 500-square-nautical-mile area near Jacksonville, Florida. Under Increments II and III, L3Harris will upgrade and replace the previously installed systems at the U.S. Navy's three other range locations near Hawaii, Bahamas and Southern California. The USWTRs enable ships, submarines and aircraft to track targets on the surface and subsurface for anti-submarine warfare training. The ranges each include more than 600 miles of undersea cables, several hundred sophisticated acoustic sensors, as well as shore-based control, display and processing facilities.

09:05 EDT Avalon GloboCare, UPMC, Pitt to develop new cancer immunotherapy - A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh and Avalon GloboCare aims to develop new cancer immunotherapy approaches and streamline manufacturing processes to bring these powerful treatments to cancer patients within days instead of weeks. Cancer immunotherapy, which stimulates and trains a patient's own immune system to target and kill tumors while leaving healthy cells intact, is an effective treatment for many cancer patients. One of these therapies, chimeric antigen receptor T-cell therapy, alters a patient's own T-cells to kill their cancer cells. This approach has been successful for some patients with leukemias, lymphomas and more recently, multiple myeloma, but only a limited number of patients have been able to benefit from these therapies. The new collaboration seeks to develop next-generation CAR-based cellular therapies to make them accessible to a wider range of cancer patients. "With Avalon GloboCare FLASH-CAR technology, we will use an innovative messenger ribonucleic acid-based technology platform that will allow researchers to create CAR cellular therapies much faster than before -- in just one to two days," said Hsu. "We also believe this approach will reduce toxicity and overall cost associated with current CAR T-cell therapies, meaning more cancer patients could be eligible for this type of cellular therapy." The researchers are also using the technology to develop next-generation, personalized CAR T-cell therapies, including engineering cells that target more than one tumor antigen, enhancing their ability to target and kill cancer cells. Hillman's IMCPL and Avalon GloboCare are developing a treatment for patients with relapsed or refractory B-cell lymphoblastic leukemia and non-Hodgkin lymphoma. Human clinical trials are poised to begin in mid-2022.

09:02 EDT Comscore signs agreement with Captivate for DOOH audience measurement - Comscore announced an agreement with Captivate, North American location-based digital video network, to provide reporting from Comscore's digital out-of-home - DOOH - solution. The new reporting includes digital ad impressions, reach, and frequency by market and demographic. Initially, Comscore will be providing Captivate with granular audience measurement across six of its networks: U.S. office elevators and lobbies; Canadian office elevators and lobbies; U.S. residential buildings; and U.S. golf clubs. Measured DOOH audiences will be made available to advertisers and agencies through Comscore Plan Metrix Multi-Platform and existing APIs. Plan Metrix combines consumers' desktop and mobile behavior with information about their lifestyles, interests, attitudes, demographics, and behaviors.

08:56 EDT Avis Budget pushing to deliver $1.5B in adjusted EBITDA this year, CFO says - CFO Brian Choi notes that $1.5B in adjusted EBITDA would be close to 2x what the company achieved in 2019. Comments taken from Q2 earnings conference call.

08:50 EDT Wikileaf to sell digital assets to Fire & Flower for $7.5M - Wikileaf Technologies announced that the Company has entered into a definitive purchase and sale agreement with Fire & Flower Holdings and Hifyre with respect to the sale of all of Wikileaf's digital assets including the website domain, www.wikileaf.com, for consideration of $7,500,000 satisfied through the issuance of common shares of Fire & Flower to be priced based on the ten trading day volume weighted average price of the Shares on the Toronto Stock Exchange as of the date of the Agreement. The Company will announce the date for an upcoming annual general and special meeting of shareholders by separate news release. At the Meeting, shareholders will be asked to consider, and if deemed advisable, to vote on the following matters: to elect the directors of the Company for the ensuing year;to re-appoint Raymond Chabot Grant Thornton LLP, Chartered Accountants as the auditors of the Company for the ensuing year and to authorize the directors to fix their remuneration; to pass, with or without variation, a special resolution authorizing the Company to complete the transaction set out above, which constitutes the sale of all or substantially all of its assets. Closing of the transaction is anticipated to occur on or before September 10 2021 and subject to a number of conditions including shareholder approval by the shareholders of Wikileaf and customary regulatory requirements.

08:47 EDT Artelo Biosciences announces publication studying plant vs synthetic cannabidiol - Artelo Biosciences announced the publication of study results in Medical Cannabis and Cannabinoids, a peer-reviewed journal. The study and related article, entitled "The Pharmacological Effects of Plant-Derived versus Synthetic Cannabidiol in Human Cell Lines," compared the in vitro effects of purified natural and synthetic forms of Cannabidiol to establish any pharmacological differences in human cell lines. The study found no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD. Gregory Gorgas, President and Chief Executive Officer of Artelo Biosciences, commented, "Since this study did not find pharmacologic differences among the CBD compositions, we believe that it is the biopharmaceutical properties that have the greatest potential to differentiate CBD products. Our CBD cocrystal should contribute to improved consistency, absorption, bioavailability, processability and stability. These properties, in turn, may lead to a product candidate with better efficacy and safety. Importantly, our patented cocrystal is comprised of both CBD and tetramethylpyrazine, each of which has have demonstrated anti-cancer properties in-vitro and in-vivo. However, individually, both of these compounds suffer from poor oral bioavailability. A recent study confirmed that when combined, there were synergistic and additive interactions between CBD and TMP in their ability to prevent cancer cell growth and to kill cancer cells. For this reason, we believe ART12.11 represents an attractive drug candidate targeting large indications, such as cancer, PTSD, inflammatory bowel disease and more. In addition, our recently issued composition of matter patents could form the basis for market exclusivity through the end of 2038."

08:44 EDT Daxor announces new data published on its BVA-100 diagnostic blood test - Daxor announces new data published in the journal Critical Care showing Daxor's unique BVA-100 diagnostic blood test provides insights into the pathophysiology of volume derangements and capillary distress in critically ill COVID-19 patients enabling improved care. The Research Letter titled "Blood volume and albumin transudation in critically-ill COVID-19 patients" studied the abnormal blood volume profiles in mechanically ventilated patients admitted to the ICU at a leading medical center in New York. The data shows that COVID-19 patients suffer from significant capillary damage and blood volume deficits that care teams became aware of through the use of the Daxor BVA-100 blood test. "Having this preliminary data published in such a prestigious medical journal as Critical Care highlights the importance of Daxor's BVA technology in helping clinicians understand COVID-based volume derangements to improve care and outcomes," said Michael Feldschuh, CEO and President of Daxor. "Daxor's BVA test is the first and only diagnostic test cleared by FDA that offers insights into patients' blood volume with a 98% accurate measure of plasma and red cell volume."

08:43 EDT Alterity Therapeutics issued patent by USPTO for neurodegenerative diseases - Alterity Therapeutics has been issued a Notice of Allowance by the USPTO which secures exclusivity for a new group of iron chaperones designed to redistribute the excess iron implicated in many neurodegenerative diseases, including Alzheimer's and Parkinson's. The patent covers more than 80 novel compounds and underwent prioritized examination by the USPTO. The notice of allowance means that the USPTO would issue the patent after certain administrative steps have been completed. The patent will confer on Alterity approximately 20 years of exclusivity over the the compounds claimed in the patent.

08:41 EDT Rogers announces exclusive Disney+ offer with select plans - Rogers Communications (RCI) announced that select Rogers Infinite plans now come with an exclusive offer of six months of Disney+ (DIS), and select Ignite TV and SmartStream plans now come with an exclusive offer of up to 12 months of Disney+ when customers sign up for a Disney+ subscription through Rogers. With summer in full swing and viewers looking to binge-watch between seasons, customers can catch their favourite movies and shows across six premium content brands available on Disney+.

08:39 EDT Compass Diversified announces simplification of tax structure - Compass Diversified announced that, on August 3, 2021, its shareholders voted to approve amendments to the governing documents of Compass Diversified Holdings to allow the Board of Directors to cause the Trust to "check-the-box" to elect to be treated as a corporation for U.S. federal income tax purposes. CODI also announced that, following the shareholder vote, the Board has resolved to cause the Trust to elect to be treated as a corporation for U.S. federal income tax purposes. Such election will be effective September 1, 2021. "We thank our shareholders for their support of this important change, which we believe presents a significant opportunity to unlock value for our current and future shareholders," said Elias Sabo, CEO of CODI. "The simplification of our tax structure is a continuation of our efforts to find more efficient ways to lower our cost of capital following the strengthening of our capital structure earlier this year. In addition, we believe that electing to be treated as a corporation for tax purposes will allow CODI to expand its shareholder base and improve the likelihood of our stock's inclusion within stock indices." "CODI expects that being treated as a corporation for U.S. federal income tax purposes will: Increase share liquidity with broadened pool of investors; Reduce weighted average cost of capital; Create more flexibility in investment decisions; Improve the likelihood of CODI's stock's inclusion within stock indices; Improve the Company's profile with ratings agencies; and Reduce administrative cost," the company said.

08:39 EDT New Frontier Health enters merger agreement for going private transaction - New Frontier Health announced that it has entered into a definitive agreement and plan of merger with Unicorn II Holdings, Unicorn II Parent, a wholly-owned subsidiary of HoldCo, and Unicorn II Merger Sub, a wholly-owned subsidiary of parent. Pursuant to the merger agreement and subject to the terms and conditions thereof, merger sub will merge with and into the company, with the company continuing as the surviving entity and becoming a wholly-owned subsidiary of parent, in a transaction implying an equity value of the company of approximately $1.58B. Pursuant to the merger agreement, at the effective time of the merger, each ordinary share of the company issued and outstanding immediately prior to the effective time, other than the excluded shares and the dissenting shares, will be cancelled in exchange for the right to receive $12.00 in cash without interest, and each outstanding warrant of the company, other than the excluded warrants, will be cancelled in exchange for the right to receive $2.70 in cash without interest. In addition to the amount of per warrant merger consideration, in respect of each warrant, other than the excluded warrants, for which the holder thereof has timely provided consent to the warrant amendment and has not revoked such consent prior to the deadline established by the company for the warrantholders to submit consents, the holder of such warrant will have the right to receive, for each such Warrant, a consent fee of 30c in cash without interest. The per share consideration represents a premium of 27.9% to the closing price of the company's shares as quoted by the New York Stock Exchange on February 8, the last trading day prior to the company's receipt of the "going-private" proposal, and a premium of 36.8% over the volume-weighted average closing price of the company's shares during the 30 trading days through February 8. .

08:38 EDT Foothills Exploration completes Phase I compliance initiative - Foothills Exploration is pleased to provide a corporate and operational update and announce the completion of its Phase I compliance initiative. On July 14, 2021, the Company filed its Q3 2020 Quarterly Report with OTC Markets and on July 21, 2021, the Company also filed its 2020 Annual Report with OTC. On July 30, 2021, the Company filed its Q1 2021 Quarterly Report enabling it to become assigned to the OTC Pink Current tier. The Company has made all the required financial information filings to become OTC Pink Current ahead of its previously announced deadline of September 30th, 2021. The Company is now working to complete the necessary steps enabling it to up-list to the OTC.QB and is beginning with the auditing process. Management is currently evaluating several small to mid-sized production and exploration opportunities in the U.S. Mid-Continent and Rocky Mountain regions to add to the Company's asset portfolio.

08:37 EDT IMV Inc. CEO Frederic Ors departs, Andrew Hall appointed interim CEO - IMV announced that Frederic Ors has stepped down as Chief Executive Officer, CEO, effective immediately. The IMV Board has appointed Andrew Hall, the Company's Chief Business Officer, as Interim CEO. The Company's Board is commencing a comprehensive search process to identify a permanent CEO. "On behalf of the Board and everyone at IMV, I want to thank Fred for his valuable contributions and years of service to IMV," said Andy Sheldon, Chairman of the IMV Board. "During Fred's tenure, IMV successfully established the Company's proprietary technology as a novel immune-oncology platform. He led the company to demonstrate the value of this approach through the successful completion of clinical trials with the platform's first development product, maveropepimut-S, proving clinical benefit for patients with both solid and liquid tumors. His vision, tenacity and leadership have been critical for building IMV's story, and we wish him all the best in his future endeavors." Mr. Sheldon continued, "As IMV advances its proprietary DPX programs and platform to benefit cancer patients and create value for shareholders, the Board determined that now is the right time to transition to new leadership. With this transition, we look forward to IMV continuing to demonstrate the clinical utility of maveropepimut-S as well as expanding its platform to create additional novel therapeutics with the potential to improve the lives of cancer patients with high unmet medical need. With multiple important trials initiated and results expected in the coming months and years, we believe we can establish IMV as a leader in oncology immunotherapy."

08:35 EDT Processa Pharmaceuticals announces first patient dosed in PCS6422 study - Processa Pharmaceuticals announced it has dosed the first patient in its Phase 1b Dose-escalation Study of the Safety and Pharmacokinetics of Fixed-dose PCS6422 With Escalating Doses of Capecitabine Administered Orally to Patients With Advanced, Refractory Gastrointestinal Tract Tumors. "We believe that the irreversible inhibitor effects of PCS6422 on the dihydropyrimidine dehydrogenase enzyme may significantly improve exposure to the cancer killing 5-FU metabolites while reducing the 5-FU metabolites, like alpha-fluoro-beta-alanine, related to dose limiting side effects such as hand foot syndrome. The dosing of the first patient in our Phase 1b trial represents an important step to explore PCS6422's potential as a disease modifying therapy for capecitabine," said Dr. Sian Bigora, Chief Development Officer. "By the end of 2021, we expect to have interim results evaluating the positive effect that PCS6422 has on capecitabine while in 2022 we anticipate being able to define a new maximum tolerated dose and potential biomarkers for the PCS6422 - capecitabine combination which will help us to define the pivotal Phase 3 study design needed for FDA approval."

08:34 EDT Vertex Pharmaceuticals appoints Stuart Arbuckle COO - Vertex Pharmaceuticals announced that Stuart A. Arbuckle has been appointed as the company's Executive Vice President, Chief Operating Officer, COO, effective immediately. Mr. Arbuckle has served as Vertex's Executive Vice President and Chief Commercial Officer since 2012 and expanded his role to include oversight of operations earlier this year.

08:31 EDT Heritage Cannabis CEO Clint Sharples to switch roles, David Schwede to succeed - Heritage Cannabis announced changes to its board of directors and appointment of a new CEO. Donald Ziraldo has recently resigned from the board of directors and his position as chair for personal reasons and to pursue other business initiatives. Clint Sharples will assume the position as chair of the board, and in conjunction with this, Sharples has stepped down as CEO of the company. The board has appointed David Schwede as his successor in the role of CEO. Schwede originally joined Heritage as president of recreational following the acquisition of Premium 5. David Schwede, Heritage's incoming CEO has been appointed as a director of the board.

08:26 EDT Cumulus Media completessale of non-core Nashville Real Estate for $34M - Cumulus Media announced that it has successfully completed the sale of non-core real estate in Nashville to a partnership comprised of Centrum Realty and Development and Nashville Capital Group for $34 million in gross proceeds. Francisco Lopez-Balboa, Executive Vice President and Chief Financial Officer of CUMULUS MEDIA, said, "We are very pleased to complete this nicely accretive non-core asset sale on a swift timeline at a value that exceeded expectations. This transaction is yet another example of our relentless focus on positioning the Company for maximum strategic and financial flexibility by continuing to de-lever the balance sheet, enhance liquidity and execute our multiple growth initiatives." With the net proceeds from the transaction, the company is required to pay down debt, pro rata between its Term Loan Credit Facility due 2026 and it 6.75% Senior Secured First Lien Notes due 2026, subject to a 12-month reinvestment right.

08:23 EDT In8bio appoints Fairbairn and Greenwood to board of directors - IN8bio announces the appointments of Emily Fairbairn and Luba Greenwood as new members of its Board of Directors. Fairbairn is currently a principal of Transcend Partners and was co-founder and CEO of Ascend Capital for nearly 20 years. Greenwood serves as Managing Partner of Binney Street Capital and co-founded and is currently CEO of LUCA Biologics. Fairbairn will be serving on the nomination and corporate governance committee, while Greenwood will be serving on the audit and compensation committees. Their terms will both expire at the annual meeting of stockholders to be held in 2022.

08:20 EDT SEC charges Live Ventures with financial, disclosure and reporting violations - The Securities and Exchange Commission charged Live Ventures, its CEO, its CFO, an LLC controlled by the CEO, and another Nevada-based public company with multiple financial, disclosure, and reporting violations related to inflated income and earnings per share, stock promotion and secret trading, and undisclosed executive compensation. The SEC's complaint alleges that Las Vegas-based Live Ventures Incorporated and its CEO, Jon Isaac, recorded income from a backdated contract to boost Live Ventures' pre-tax income for FY16 by 20%. Live Ventures and Isaac also allegedly overstated earnings per share by 40% by improperly understating Live Ventures' outstanding share count. The complaint alleges that in addition to disclosing falsified financial results, Isaac hired a stock promoter to boost interest in Live Ventures. As alleged, the financial manipulation and stock promotion caused Live Ventures' share price to spike. Isaac allegedly profited by secretly selling Live Ventures shares in a nominee account that he controlled in the name of Kingston Diversified. The complaint also alleges that Live Ventures misrepresented the date on which it had acquired a new subsidiary from Appliance Recycling Centers of America, enabling Live Ventures to report a positive net income for Q1 of 2018, which otherwise would have been an unprofitable quarter. According to the complaint, Isaac and Virland Johnson, who held the position of CFO at both Live Ventures and ARCA, engaged in a scheme to misrepresent the effective acquisition date, and lied to Live Ventures' auditors about the acquisition date to ensure Live Ventures could report positive net income. The complaint further alleges that Isaac underreported his executive compensation in Live Ventures' proxy statements. As alleged, for the fiscal years 2016, 2017, and 2018, Live Ventures disclosed that Isaac received, in aggregate, $162,000 of additional compensation, even though he had actually received approximately $315,000 during that period. Reference Link

08:16 EDT Capricor Therapeutics announces joint publication with US Army Institute - Capricor Therapeutics announced the publication, of a manuscript, which shows that cardiosphere-derived exosomes can attenuate kidney damage and promote new blood vessel formation in a preclinical model of acute trauma, both of which are important factors in post-shock recovery. The publication titled, "Extracellular vesicles derived from cardiosphere-derived cells as a potential antishock therapeutic" was published in the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery in collaboration with researchers at the United States Army Institute of Surgical Research. "I am very excited to share the published results of this important study," said Linda Marban, Ph.D., Capricor's CEO, "This has been a key collaboration between the USAISR and Capricor and shows the importance of CDC-EVs as a potential anti-shock therapeutic. The military continues to look for therapeutics that can be delivered in the field to stabilize wounded warriors. While cell therapy held promise in that arena, a lyophilized product that does not require ultra-cold storage is preferable. We believe that our CDC-EVs could potentially be that product. While further work is required to elucidate the full extent of possible clinical implications for CDC-EVs in treating trauma, these results certainly are a very important first step in that evaluation. We are delighted to work with the USAISR and look forward to extending this collaboration." The goal of the study was to determine the therapeutic potential of CDC-EVs in a rat model of acute traumatic coagulopathy induced by polytrauma and hemorrhagic shock. CDC-EVs were not functionally procoagulant and did not interfere with platelet function, a pathological feature of acute polytrauma which was not ameliorated by another source of EVs, made from MSCs, in vitro. The findings suggest early delivery could improve outcomes of polytrauma and hemorrhagic shock, which is possible in the field due to the ease of utility, possibly being carried in a medic's pack.

08:15 EDT PAE-Perini awarded $38.6M task order on Air Force Contract Augmentation Program - The U.S. Air Force has awarded PAE-Perini LLC a task order on the Air Force Contract Augmentation Program V contract vehicle to provide installation support and sustainment services to the 724th Expeditionary Air Base Squadron in Agadez, Niger. The total evaluated price is $36.8M. PAE-Perini is a joint venture between PAE and Perini Management Services. On this task order, PAE-Perini will provide civil engineering support, including operations, maintenance and repair services and force support services for mission partners and personnel through September 2026.

08:14 EDT Iridium's Certus connectivity selected by Canadian Coast Guard - Iridium announced that the Canadian Coast Guard has adopted Iridium Certus connectivity with support from Iridium partner MetOcean Telematics. The Coast Guard deployed dozens of Iridium Certus Thales VesseLINK 700 terminals on its vessels, including icebreakers, to contribute to internet connectivity. Iridium Certus connectivity supports the Coast Guard's general safety with access to navigational data and weather reports, which is a large improvement from historical solutions.

08:12 EDT Beyond Meat expands partnership with A&W Canada to launch Beyond Meat Nuggets - Beyond Meat announced another exciting milestone in its partnership with A&W Canada with the introduction of Beyond Meat Nuggets. "Beyond Meat Nuggets couldn't come at a more perfect time," said Deanna Jurgens, Chief Growth Officer, Beyond Meat. "We've doubled down on plant-based chicken this summer, just as consumer demand for chicken is skyrocketing. Following the success of our partnership on the Beyond Burger, we're proud to be working with A&W Canada to debut Beyond Meat Nuggets in Canada." As part of the company's expanding plant-based poultry platform, Beyond Meat has been making strides in plant-based chicken in recent weeks, including the launch of Beyond Chicken Tenders in the U.S. Beyond Meat Nuggets, a brand new product, are making their debut at A&W Canada locations nationwide, marking an important milestone between Beyond Meat and A&W Canada as they work to bring increased choice and more diverse protein options to menus.

08:11 EDT Inovio doses first participant in Phase 2 trial for MERS vaccine - Inovio has dosed the first Phase 2 trial subject in its quest to develop the first vaccine against the Middle East Respiratory Syndrome, or MERS. INOVIO's Phase 2 trial is designed to evaluate INO-4700, its DNA vaccine candidate for the prevention of MERS, a disease in the coronavirus family for which there are no approved vaccines. The Phase 2 trial is designed to evaluate the safety, tolerability, and immunogenicity of INO-4700 administered with Inovio's smart device, the Cellectra 2000, in approximately 500 healthy adult volunteers. The study, which is sponsored by Inovio and fully funded by the Coalition for Epidemic Preparedness Innovations, is being conducted at sites in Jordan and Lebanon where MERS cases have been reported. This trial builds on the positive results of the Phase 1 trial. Results from this first-in-human Phase 1 trial found high levels of binding antibodies in 92% of evaluated subjects. Significant antigen-specific cytotoxic T-lymphocyte responses were also observed. 98% of vaccinated subjects generated an antibody and/or T cell response against the MERS vaccine.

08:09 EDT InnovAge makes equity investment in Jetdoc - InnovAge announced that it has made an equity investment in telehealth platform Jetdoc, a telehealth and virtual urgent care app. InnovAge will also partner with Jetdoc to develop a virtual care and remote patient monitoring platform purpose-built for participants and caregivers of the Program of All-inclusive Care for the Elderly, or PACE. The platform will be designed to support the unique PACE interdisciplinary care model, in which each senior in the program has a team of medical experts assigned to their care team. Additionally, Alice Raia, chief information officer of InnovAge, has joined Jetdoc's board of directors. "Ever since the Centers for Medicare & Medicaid Services issued guidance to PACE organizations in March 2020 in response to the coronavirus pandemic, telehealth has become an important tool as we help seniors live independently and in their own homes for as long as safely possible," said InnovAge President and CEO Maureen Hewitt. "The accelerated adoption of telehealth brought on by COVID-19 has demonstrated the need to have a platform that works with the unique aspects of the PACE model, including our interdisciplinary team approach. Partnering with Jetdoc will allow us to build upon a proven technology solution and work with a leading provider of access to virtual care."

08:06 EDT Zoetis to acquire animal health company Jurox, terms undisclosed - Zoetis announced it has entered into an agreement to acquire Jurox, a privately held animal health company, which develops, manufactures and markets a wide range of veterinary medicines for treating companion animals and livestock. Jurox's operations are based in Australia, with additional regional offices and subsidiaries in New Zealand, U.S., Canada and the UK. Financial terms of the transaction are not being disclosed. Once completed, the acquisition of Jurox will bring Zoetis a range of important products primed for greater global expansion; a valuable animal health portfolio, including Alfaxan, a leading anaesthetic product for companion animals; and high-quality, local manufacturing operations in Australia, a critical region for growth. Australia is Zoetis' fifth largest market, based on $207 million in revenue in 2020.

08:05 EDT Royal Caribbean expects to incur a net loss for Q3, FY21

08:04 EDT Royal Caribbean: Bookings volumes have improved, pricing 'strong' - The company said: "Overall booking volumes have improved, and pricing remains strong. During the second quarter the Company received about 50% more new bookings compared to the first quarter with trends improving from one month to the next. By June, the Company was receiving about 90% more bookings each week when compared to the first quarter with improvements of a similar magnitude for both 2021 and 2022 sailings. The surge in bookings has been extremely encouraging especially for 2022 and beyond. The return of cruising has been faster than anyone expected, and we are excited to gradually restart our presence in our key markets. We are watching the impact of the Delta variant and other likely variants, but overall, we remain optimistic in our mounting trajectory going forward. People also book their cruises long in advance, so we are concentrating on maintaining our price levels while growing our load factors. Overall, the booking activity for 2021 sailings is consistent with the Company's expected capacity and occupancy ramp up, at prices that are higher than 2019. While it's too early to make any definitive conclusions of the impact of the Delta variant on bookings, the company has seen a modest impact on closer-in bookings. However, 2022 continues to remain strong; in particular the spring and summer months are performing well."

08:04 EDT Aditx Therapeutics announces Psoriasis clinical program pushed back to 2022 - Aditxt Therapeutics announced its Psoriasis clinical program will now be slated for 2022 instead of December as previously announced. The updated timeline is due to a lengthier large scale clinical grade manufacturing and approval process for initiating toxicology studies. Meanwhile, Aditxt has continued to strengthen the data set that will be supporting regulatory submissions for the Apoptotic DNA Immunotherapy platform for evaluation of ADi in clinical studies for skin allografting and type 1 diabetes in addition to the trials planned for psoriasis. The company is also announcing the expansion of its preclinical ADi program to include antigen-specific immune cell modulation for multiple sclerosis, or MS, alongside its existing projects focused on type 1 diabetes and skin allografting. Broadening the therapeutic programs to include MS is intended to address an important clinical need in addition to demonstrating the utility of ADi as an antigen-specific immune tolerance platform.

08:03 EDT Royal Caribbean: Operating 29 ships across brands, or 42% of capacity - The group is operating 29 ships across its five brands, representing 42% of capacity. By the end of this month, the group expects to be operating 36 ships, representing over 60% of its capacity. The company anticipates having 80% of its capacity in service by end of year 2021. Booked load factor for 2022 is within historical ranges. Prices for 2022 are up versus a record-setting 2019, even including the dilutive impact of future cruise credits. Customer Deposits have increased $530M from last quarter to $2.4B. The company ended the second quarter with $5B of liquidity.

07:59 EDT Nuvista Energy sees 2021 capital spending C$230M-C$250M - NuVista is pleased to note that both condensate and natural gas future strip prices have increased significantly, resulting in a material increase to projected cash flows and decreasing debt levels. Our continuing efforts will be to focus on a disciplined capital program to maximize economic returns from our existing facilities, and rapid debt repayment NuVista's capital spending guidance for 2021 remains at $230 - $250 million. Keeping the schedule smooth and full for existing rigs is increasingly fundamental to retaining high quality rigs and crews in this tightening and inflationary environment. This leads to the maximization of efficiency, cost, and safety performance. Full year 2021 production guidance is re-affirmed at 50,000 - 52,000 Boe/d, and third quarter production guidance is 50,000 - 52,000 Boe/d prior to the fourth quarter ramp-up in production as our post spring breakup wells begin to come online. We continue to forecast significant ongoing reduction of net debt as well as dramatic reduction in net debt to cash flow ratio. At strip prices, we anticipate exiting 2021 with a net debt to annualized fourth quarter cash flow ratio of less than 1.2x. Net debt at year end 2021 is anticipated to be below $520 million, a reduction of almost $140 million from the peak during the 2020 pandemic, with free cash flow driving a further reduction to approximately $400 million by the end of 2022. We intend to continue our track record of carefully directing additional available cash flow towards a prudent balance of net debt reduction and production growth until our existing facilities are filled to maximum efficiency, and net debt to cash flow levels reach 1.0x or less. Capital spending will continue to be weighted heavily towards Pipestone, as our highest return area, with expected well payouts well below a year. NuVista retains the flexibility to adjust capital spending should commodity prices increase or retreat significantly from the current positive trend. NuVista has a solid business plan that maximizes free cash flow and the return of capital to shareholders when our existing facilities are filled to capacity and maximum efficiency at flattened production levels of approximately 80,000 - 90,000 Boe/d. We are confident that the actions described above accelerate the Company towards that goal by as early as 2023, while still providing free cash flow and net debt reduction while growing through 2021-2023. With facilities filled, returns and netbacks are enhanced significantly due to efficiencies of scale, with overall cash costs which are expected to reduce by over 25%, or approximately $6/Boe by 2023 as compared to the first quarter of 2021.

07:57 EDT Schrodinger, Zai Lab announce oncology collaboration - Schrodinger (SDGR) and Zai Lab (ZLAB) announced a global discovery, development and commercialization collaboration focused on a novel program in oncology targeting DNA damage response. The research program will be conducted jointly by the Schrodinger and Zai Lab scientific teams. The companies will be responsible for their own research program expenses, and under the terms of the collaboration agreement, Zai Lab will make an upfront payment to Schrodinger to help fund Schrodinger's share of research costs. Following the selection of a development candidate, Zai Lab will assume primary responsibility for global development, manufacturing and commercialization. The agreement provides Schrodinger co-development and co-commercialization rights in the U.S. If Schrodinger elects to co-fund clinical development of a product candidate under the collaboration, it will be entitled to 50% of the profits, if any, from the commercialization of such product candidate in the United States. Schrodinger will also be eligible to receive up to approximately $338M in preclinical, clinical, regulatory and sales-based milestone payments. Additionally, Schrodinger is entitled to receive royalties on net sales outside the U.S.

07:53 EDT Sensei Biotherapeutics expects cash to fund operations into 1H of 2024 - Cash, cash equivalents and marketable securities were $162.5 million as of June 30, 2021, as compared to $16.6 million as of December 31, 2020. Sensei expects the current cash balance to fund operations at least into the first half of 2024.

07:51 EDT Trimble announces $200M venture fund - Trimble announced the creation of Trimble Ventures, a venture fund focused on investing in companies that align with Trimble's mission of transforming work in the agriculture, construction, geospatial and transportation industries. The fund will launch with $200M allocated for investments and focus on companies with the potential for technology-enabled innovation and disruption in the digital transformation of the industries Trimble serves.

07:47 EDT BioDelivery Sciences enters agreement to acquire U.S., Canadian rights to ELYXYB - BioDelivery Sciences announced that it entered into an agreement on August 3, 2021 with Dr. Reddy's Laboratories Limited to acquire the U.S. and Canadian rights to ELYXYB. "ELYXYB represents an excellent strategic fit for BDSI and a very attractive opportunity to diversify our product portfolio by expanding into the dynamic migraine market, deepening our presence in Neurology, a logical adjacency to our pain franchise," stated Jeff Bailey, CEO of BDSI. "ELYXYB will contribute nicely to the Company's revenue growth and profitability over time. This transaction leverages our commercial expertise and much of our existing infrastructure. We see this acquisition as establishing a great growth platform in Neurology. Further, the deal structure is attractive, allowing us to maintain our strong balance sheet and position us to pursue additional value-enhancing business development opportunities," Bailey concluded. Under the terms of the agreement, ELYXYB will be acquired for an upfront payment of $6M, plus an additional $9M on August 3, 2022. BDSI will make tiered quarterly earn-out payments on potential net sales ranging from the high single digits to the low double digits. Additional payments will be made contingent upon the achievement of certain regulatory and sales milestones. The impact of the acquisition is estimated to be cash flow accretive within approximately 24 months of commercial launch, currently planned for Q1 2022.

07:44 EDT Hudson Capital appoints Luisa Lopez as Chief Operating Officer - Hudson Capital announced that FreightHub, a North American transportation logistics technology platform company focused on US-Mexico cross-border shipping with which Hudson Capital has signed a definitive Merger Agreement, appointed Luisa Irene Lopez as its new Chief Operating Officer, effective August 2, 2021. Lopez will report to Javier Selgas, Fr8Hub's Chief Executive Officer, and will be responsible for overall business strategy, operations, customer service, and strategic vendor oversight.

07:42 EDT 36Kr Holdings content to be included on Bloomberg terminals globally - 36Kr Holdings' content has been included in Bloomberg Terminal news feeds. Users can now access 36Kr news articles on the Bloomberg Terminal.

07:42 EDT FMC Corporation targets net-zero greenhouse gas emissions by 2035 - FMC Corporation announced its goal to achieve net-zero greenhouse gas emissions by 2035. The company will use science-based targets aligned with keeping the global temperature at 1.5 degrees C above pre-industrial times. "FMC's net-zero emissions target is a bold step in our continuing commitment to sustainable innovation and operations," said Karen Totland, FMC vice president and chief sustainability officer. "We are engaging key organizations across our company-including Manufacturing, Supply Chain, Environment, Health and Safety, Procurement and R&D-to improve efficiencies, invest in renewable energy sources and engage with third-party suppliers to reduce their emissions. We are proud to build on FMC's past successes in energy and resource reduction, and look forward to working together with suppliers and other partners to achieve this ambitious goal."

07:41 EDT Else Nutrition completes manufacturing run of plant-based products - ELSE NUTRITION announces that after months of R&D and trials, it has successfully completed a full-scale commercial trial manufacturing run of ready to drink liquid version of its Plant-Based Complete Nutrition for Toddlers and Kids products. Else intends to further use this capability to drive growth in the Kids and Toddler RTD markets across many geographies and sets the stage for being able to offer its planned infant formula in liquid format, upon receipt of FDA approval. The capacity to offer Else products in liquid format further enables the brand to penetrate hospitals with a long-awaited, Plant-Based liquid formula alternative, therein creating a critical competitive advantage for the Else brand. The hospital channel is of paramount importance in a parent/caregivers' decision-making process when it comes choosing a formula for their baby/child.

07:40 EDT BeyondSpring announces results from its DUBLIN-3 registrational trial - BeyondSpring announced the "positive" topline data of DUBLIN-3 registrational trial in plinabulin in combination with docetaxel to treat 2nd and 3rd line NSCLC compared to docetaxel alone. Plinabulin is a first-in-class, selective immunomodulating microtubule-binding agent, which is a potent antigen presenting cell inducer. The data released today showed that compared to docetaxel alone, the combination met the primary endpoint of increasing overall survival and met key secondary endpoints, including significantly improving ORR, PFS and 24- and 36-month OS rates, and significant reduction in the incidence of Grade 4 neutropenia. The DUBLIN-3 Phase 3 trial is a randomized, single blind to patients, active controlled, global trial that enrolled 559 patients in 2nd and 3rd line NSCLC, EGFR wild type, with measurable lung lesion. Patients were treated on a 21-day cycle with infusion of docetaxel and plinabulin vs. docetaxel alone. The primary endpoint was overall survival. Plinabulin in combination with docetaxel showed statistically significant improvements compared to docetaxel alone with topline data summarized below for ITT population. Dr. Lan Huang, BeyondSpring's co-founder, CEO and Chairwoman concluded, "A pre-NDA meeting will be scheduled with the FDA in 2021 to agree on the contents for our NDA, to support a NSCLC indication NDA submission in the first half of 2022. This will be the second indication and second NDA for plinabulin. The superior benefit of plinabulin in reducing severe neutropenia of docetaxel in DUBLIN-3 further supports our first NDA submission in CIN prevention, which received FDA priority review with a PDUFA date of November 30, 2021. Importantly, the strong results from DUBLIN-3 further validate our conviction that plinabulin, as an immune anti-cancer agent, has the potential to be a cornerstone therapy for many solid tumors. I'd like to take the time to thank everyone who helped make this 6-year study run smoothly at more than 60 sites across the U.S., China and Australia, including all participating patients and their families, the investigators and clinical staff and the dedicated BeyondSpring team."

07:38 EDT Schnitzer West selects View smart windows for office - View announced its smart windows will be installed at The Current, River North, a 235,000-square-foot, a Class-A office building designed to promote tenant health, wellbeing and productivity. The development, a joint venture partnership between Schnitzer West and Craft Companies, represents the second View project for Schnitzer West, following the installation of View Smart Windows at Civica Cherry Creek, a mixed-use development which achieved the highest weighted average rent in Denver when it delivered in 2018. Schnitzer West and Craft Companies designed The Current, River North to be an ecosystem of innovation in Denver's up-and-coming River North Art District. The building features multiple amenities, including View Smart Windows, which use artificial intelligence to automatically adjust to optimize access to natural light and views of the outdoors while controlling temperature and glare.

07:36 EDT AC Immune expects cash to fund operations through at least 1Q24 - The Company had a total cash balance of CHF 199.1 million, composed of CHF 104.1 million in cash and cash equivalents and CHF 95.0 million in short-term financial assets. This compares to a total cash balance of CHF 225.9 million as of December 31, 2020. The Company's cash balance provides enough capital resources to progress through at least Q1 2024 without consideration of potential incoming milestone payments.

07:35 EDT Clean Harbors raises FY21 adjusted EBITDA view to $620M-$650M - "We enter the second half of 2021 with considerable momentum across all our key markets, backed by a promising North American economic environment. We expect a record-setting financial year for the Company," McKim concluded. "Within our Environmental Services segment, we see encouraging signs for steady waste volumes, project work and rising demand for our broad suite of service offerings. With the planned acquisition of HydroChemPSC, we will significantly bolster our capabilities within Industrial Services and Field Services while driving more volumes into our network. Within our SKSS segment, we see our used oil to base oil pricing spread extending until later in the year, and we will continue to see the benefits of separating out this segment. We will continue to capitalize on the opportunities afforded by these current market conditions, and look forward to adding the Vertex facilities, personnel and waste oil collection assets to this segment. Overall, we continue to maintain a favorable outlook in both of our segments for the remainder of the year and into 2022." Based on its second-quarter financial performance and current market conditions, Clean Harbors is raising its 2021 guidance. For the year, the Company currently expects: Adjusted EBITDA in the range of $620 million to $650 million, based on anticipated GAAP net income in the range of $159 million to $193 million; and Adjusted free cash flow in the range of $285 million to $315 million, based on anticipated net cash from operating activities in the range of $475 million to $525 million.

07:30 EDT MannKind, NRx Pharmaceuticals partner to evaluate powder formulation of Zyesami - MannKind (MNKD) has partnered with NRx Pharmaceuticals (NRXP) to evaluate the feasibility of formulating a dry powder formulation of Zyesami, a synthetic form of human Vasoactive Intestinal Peptide, or VIP, - an endogenous substance produced by the body that helps protect cells against inflammatory conditions. An intravenous formulation of Zyesami is currently in clinical trials, having been granted fast track designation by the FDA for the treatment of Critical COVID-19 with Respiratory Failure. MannKind will begin exploring formulation potential at its research and manufacturing facility located in Danbury, Connecticut, which features a full range of development and manufacturing capabilities, including analytical, chemical, formulation, filling and packaging. It has sufficient filling capacity to produce more than 300M cartridges of inhaled drug annually.

07:30 EDT BeyondSpring trading resumes

07:27 EDT Clean Harbors to acquire HydroChemPSC for $1.25B in all-cash transaction - Clean Harbors announced it has entered into a definitive agreement to acquire HydroChemPSC, or HPC, from an affiliate of Littlejohn & Co. for $1.25B in an all-cash transaction. HPC is a U.S. provider of industrial cleaning, specialty maintenance and utilities services. The acquisition, which is subject to regulatory approval and other customary closing conditions, is expected to close in 2021. With more than 240 service locations throughout the country, HPC serves a broad range of end markets including refining, chemical and utilities. Its services are built around providing solutions to customers focused on cleaning, maintenance and environmental compliance of essential, mission critical equipment and infrastructure. HPC has more than 5,000 employees and operates a fleet of specialized vehicles and equipment. The fleet consists of more than 5,600 units including vacuum trucks, roll-off trucks, high pressure water blasters, and light duty vehicles. In addition, HPC is the only provider of industrial cleaning and specialty services with a dedicated manufacturing and technology center. HPC's proprietary technology and ability to fabricate and create custom tools for complex or unique applications gives them a true competitive advantage. The company said the deal captures significant synergies in areas such as customer service, transportation, branch network, asset rentals, vehicle and tank refurbishment, subcontracting and procurement.

07:25 EDT New York Times sees Q3 total subscription revenue up 13%-15% - Sees Q3 total advertising revenue up 30%-35%. Sees FY21 capital expenditures $50M.

07:23 EDT Editas Medicine expects cash to fund operating expenses well into 2023 - Cash, cash equivalents, and marketable securities as of June 30, 2021, were $698.1 million, compared to $723.2 million as of March 31, 2021. The Company expects that its existing cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditures well into 2023.

07:22 EDT Charles River sees FY21 interest expense $90M-$93M

07:20 EDT Charles River well positioned to achieve op. margin target of 22.5% in 2024 - Comments taken from Q2 earnings conference call presentation slides.

07:18 EDT Orchard Therapeutics expects cash to fund requirements into 1H23 - Cash, cash equivalents and investments as of June 30, 2021, were $269.3 million compared to $191.9 million as of December 31, 2020 and excludes the $17.5 million in upfront payments from the collaboration with Pharming Group N.V. entered into on July 1, 2021. The increase was primarily driven by net proceeds of $143.6 million from the February 2021 private placement, offset by cash used for operating activities and capital expenditures. The company expects that its cash, cash equivalents and investments as of June 30, 2021 will support its currently anticipated operating expenses and capital expenditure requirements into the first half of 2023. This cash runway excludes the additional $67 million that could become available under the company's credit facility and any non-dilutive capital received from potential future partnerships or priority review vouchers granted by the FDA following future U.S. approvals.

07:16 EDT TD Holdings to establish subsidiary at Yangzhou Development Zone - TD Holdings has entered into a strategic cooperation agreement with the management committee of the Yangzhou Economic & Technological Development Zone, a national level economic and technological development zone in China. The company agreed to establish its new wholly-owned subsidiary Yangzhou Baiyu Venture in the Zone and the management committee of the Zone agreed to grant the company preferential policies including financial subsidies, tax relief, financial support, rental subsidies, etc.

07:14 EDT Criteo says Best Buy signs on to company's retail media ecosystem and platform - Criteo (CRTO) announced a new milestone: consumer electronics retailer, Best Buy (BBY), a longstanding Criteo customer, has signed on to the company's retail media ecosystem and platform. As of August, advertisers can use Criteo's cross-retailer, self-service platform to reach BestBuy.com and BestBuy.ca shoppers in the U.S. and Canada. Through sponsored products, the platform will help customers further discover and purchase the products they need.

07:11 EDT Morphic expects cash to fund requirements until the end of 2024 - As of June 30, 2021, Morphic had cash, cash equivalents and marketable securities of $431.6 million, compared to $228.3 million as of December 31, 2020. Morphic believes its cash, cash equivalents and marketable securities as of June 30, 2021, will be sufficient to fund operating expenses and capital expenditure requirements until the end of 2024.

07:06 EDT Red White & Bloom Brands subsidiary closes acquisition of greenhouse - Red White & Bloom Brands strategically advanced its cultivation and production initiatives in the Florida market, with the purchase of a fully operational greenhouse in Apopka, Florida. Red White & Bloom Florida, a Red White & Bloom Brands subsidiary, has closed on the acquisition of an operational 45,000 square foot greenhouse situated on 4.7 acres of land in Apopka, Florida. The Red White & Bloom team will begin rapid development on the facility to ensure all compliance standards are achieved for a Q4 2021 harvest schedule. This acquisition comes directly on the heels of the Sanderson Florida purchase and provides immediate benefits for significant cultivation expansion for delivery to RWBFL stores in Florida. RWB's brands include iconic names such as High Times and the successful Michigan and California 'Platinum' line. The company will brand its Florida medical dispensaries beginning in Q4 and is developing a consistent retail footprint and product line to align with the medical market in Florida. The addition of the Apopka cultivation center will not only facilitate the product selection plan RWB as for its branded dispensaries but is also projected to add an additional 40-50 employment opportunities for the local community when fully operational. The Company and RWB Florida LLC completed a Real Estate Purchase and Sale Agreement for a purchase price of $1,875,000 payable as to: US $750,000 cash paid on closing; US $125,000 in the form of promissory note of RWB Florida LLC payable in 5 monthly instalments commencing 30 days after Closing; and $1,000,000 worth of RWB Common Shares at a price of $1.22, being 1,010,656 shares. The shares issued are subject to regulatory resale restrictions in accordance with both US and Canadian securities laws.

07:04 EDT MGM Resorts to receive cash proceeds of $4.4B

07:02 EDT MGM Resorts: VICI Properties to acquire MGM Growth in deal valuing MGP at $17.2B

07:00 EDT FTAC Athena Acquisition Corporation (Class A Stock) trading halted, news dissemination

06:55 EDT BeyondSpring trading halted, news pending

06:53 EDT Ault Global Holdings makes investment in Alzamend Neuro - Ault Global's (DPW) wholly owned subsidiary Digital Power Lending has made an additional investment in Alzamend Neuro (ALZN). On July 28, Alzamend received a "study may proceed" letter from the FDA for a Phase 1a study under Alzamend's Investigational New Drug application for AL001, a lithium-based ionic cocrystal oral therapy for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer's disease. Based on the achievement of this milestone, under the March 12 securities purchase agreement, Alzamend sold an additional 1,333,333 shares of its common stock to DPL for $2M, or $1.50 per share, and issued to DPL warrants to acquire 666,667 shares of its common stock with an exercise price of $3.00 per share. The premise of this investment into Alzamend was to provide Alzamend a committed source of capital, driven by milestones, to fund Alzamend's therapeutic treatments through the end of Phase 1 clinical trials. A third tranche in the amount of $4M for the purchase of an aggregate of 2,666,667 shares and warrants to purchase an additional 1,333,333 shares shall be issued to DPL upon DPL receiving written confirmation from Alzamend that its Phase 1a human clinical trial for AL001 has been completed.

06:49 EDT ANYbotics boosts autonomous mobile robots with Velodyne Lidar sensors - Velodyne Lidar announced ANYbotics is equipping its autonomous mobile robots with Velodyne's Puck lidar sensors. ANYbotics robots provide industrial operators with an automated robotic inspection solution to support efforts in monitoring and maintaining plants.

06:39 EDT AmerisourceBergen raises FY21 adjusted free cash flow view to $1.7B from $1.5B - Additional FY21 expectations now include: Adjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range; Adjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range; Pharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from growth in the high-single digit percent range; Other, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health businesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit percent range; and Adjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.

06:15 EDT KBR signs technology contract for sustainable textile plant in Sweden - KBR announced that it has signed a technology contract for a sustainable textile fibers demonstration plant to be built by TreeToTextile in Nymolla, Sweden. KBR will provide technology license, engineering, proprietary equipment, and commissioning services for the chemicals recovery unit of the project, which will enable TreeToTextile to efficiently and sustainably reuse valuable chemicals through KBR Ecoplanning solutions.

06:14 EDT Patterson-UTI reports an average of 78 drilling rigs operating in July - Patterson-UTI reported that for the month of July, the company had an average of 78 drilling rigs operating. Average drilling rigs operating reported in the company's monthly announcements represent the average number of the company's drilling rigs that were earning revenue under a drilling contract.

06:09 EDT Conn's names Chandra Holt as new CEO, succeeding Norm Miller - Conn's (CONN) announced it has appointed Chandra Holt as the company's new CEO and President, effective August 9. She will also join Conn's Board of Directors increasing the number of directors to nine. Holt's appointment as CEO and President of Conn's follows the Board's multi-year succession planning process. Holt succeeds Norm Miller, who will transition to the role of Executive Chairman. Most recently, Chandra Holt led Walmart's (WMT) multi-billion-dollar U.S. eCommerce business, delivering over 70% growth in FY21.

06:08 EDT Worksport announces uplisting to Nasdaq, reverse stock split - Worksport Ltd. announced the pricing of its underwritten public offering of 3,272,727 units at a price to the public of $5.50 per unit. Each unit issued in the offering consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $6.05. The common stock and warrants are immediately separable and will be issued separately. The common stock and warrants are expected to begin trading on the Nasdaq Capital Market on August 4, 2021, under the symbols "WKSP" and "WKSPW," respectively. Worksport expects to receive gross proceeds of $18M, before deducting underwriting discounts and commissions and other estimated offering expenses. In connection with the offering, the company will effectuate a reverse split of its issued and outstanding common stock at a ratio of 1-for-20. The reverse stock split is expected to be effective at 12:01 a.m., Eastern Time, on Wednesday, August 4, 2021. Worksport has granted the underwriters a 45-day option to purchase up to an additional 490,909 shares of common stock and/or an additional 490,909 warrants at the public offering price to cover over-allotments, if any. The offering is expected to close on August 6, 2021, subject to customary closing conditions. Maxim Group LLC is acting as sole book-running manager for the offering.

06:04 EDT Lumber Liquidators plans for 'slowing comparable sales' in 2H21 - The company said, "For the foreseeable future, there remains uncertainty in the macro environment related to consumer spending as well as global supply chain disruptions, and the potential impact of the COVID-19 Delta variant. As a result, while we are pleased with the traction we are gaining on our transformation initiatives, we are not providing financial guidance at this time. However, we believe it is prudent to plan for slowing comparable sales on a two-year stack basis for the second half of 2021 compared to the 10% two-year stack comparable sales we delivered in the second quarter."

05:34 EDT Juniper joins SoftBank 5G consortium - Juniper (JNPR) announced that it has joined the Softbank 5G Consortium established by Softbank (SFTBY), as a founding member, having been named as a 5G-related partner. As long-time partners, Juniper Networks and Softbank have grown together over the years into the 5G era. In particular, Juniper's automated and secure IP networking solutions, including its flagship MX Series Universal Routing Platforms, play a role in the development of Softbank's 5G infrastructure. The Softbank 5G Consortium brings together partners, operators, industry experts and companies in 5G-related fields, to collaborate alongside Softbank on proof-of-concept demonstrations aimed at addressing the commercialization and adoption of 5G solutions across various industry verticals.

05:26 EDT Callon Petroleum to acquire Primexx Energy Partners for $788M in cash, stock - Callon Petroleum announced an agreement to acquire the leasehold interests and related oil, gas, and infrastructure assets of Primexx Energy Partners and its affiliates. Primexx is a private oil and gas operator in the Delaware Basin with a contiguous footprint of 35,000 net acres in Reeves County and second quarter 2021 net production of approximately 18,000 barrels of oil equivalent per day. The cash and stock transaction is valued at approximately $788M, representing a headline purchase price multiple of approximately $43,800 per Boe/d, based on second quarter production. With approximately 300 identified core net locations, approximately two-thirds of which are two-mile laterals, the acquired assets will support Callon's continued shift to larger, more capital efficient development projects in the Delaware Basin. Additionally, the acquisition increases the oil cut of Callon's Delaware business and improves corporate-level cash margins. Kimmeridge has agreed to convert their remaining portion of the Callon second lien senior notes that were issued in 2020 into common shares after the close of the Primexx transaction. This equitization further advances the company's deleveraging timetable and saves nearly $20M per year in interest costs.

05:19 EDT H.B. Fuller to build new facility in Cairo - H.B. Fuller announced a strategic investment to build a new facility in Cairo to support customers' increased demand in the markets of Egypt, Turkey, Middle East and Africa. The new factory will become a regional supply hub and a center of excellence for manufacturing for adhesives serving the hygiene, packaging, labelling, paper converting and graphic arts, among other industries. The production facility will fulfil sustainability standards. With a gross area of 37,000 square meters in a two-story building, the planned site will be built at the CPC Industrial Park, on October 6 in an industrial city in Cairo, which is considered a strategic location for manufacturing, and will commence full production in the last quarter of 2022.

05:02 EDT Clarivate acquires Bioinfogate, terms undisclosed - Clarivate announced that it has acquired Bioinfogate, a provider of analytics solutions in the life sciences and producer of the OFF-X portal. Financial terms of the transaction were not disclosed. The Bioinfogate OFF-X portal is a safety intelligence solution aimed at empowering pharmaceutical organizations to identify toxicology and safety signals, mitigate safety liabilities and de-risk early-stage assets. It is one of the largest translational safety and toxicityportals, featuring over 1,200,000 safety alerts corresponding to over 23,000 drugs and biologics and more than 15,000 targets of pharmacological interest.